Evaluating the Patient for Treatment/Readiness

Lisa Townshend-Bulson, MSN, APRN, FNP-BC
Disclosure

I am a principal investigator for an ANTHC sponsored HCV treatment study funded in part by Gilead Sciences
Who to Treat

Treatment is recommended for all patients who have **chronic** HCV infection except:

- Those with a short life expectancy that cannot be remediated by HCV treatment, liver transplantation, or another directed therapy.

AASLD/IDSA HCV Guidance, May 2018   www.hcvguidelines.org
Evaluation Essentials

____ Confirmation of HCV
____ Chronic vs. acute disease
____ Past treatment status
____ Fibrosis stage
____ Identify/address significant comorbidities
____ Immunizations as appropriate (Hep A&B)
____ Check drug interactions
____ Know pregnancy/plans/birth control
____ Determine patient readiness – any PTDs?
____ Insurance status/prior authorization
Hepatitis C Virus Confirmation

Anti-Hepatitis C Antibody → POSITIVE → Hepatitis C RNA Test (Viral Load) → POSITIVE → PERSON HAS ACTIVE HEPATITIS C INFECTION

Clinical Follow-Up Needed

www.anthctoday.org/community/hep/providers
http://www.hcvguidelines.org/full-report-view
Acute vs Chronic HCV

• Acute HCV: defined as presenting within 6 months of exposure

• Approximately 20%-50% will clear HCV spontaneously- 2/3 within the first 6 months of infection

• Monitor HCV RNA and LFTs for at least 6 months to determine spontaneous clearance
  • If you decide to treat acute HCV, monitor HCV RNA for at least 12-16 weeks before beginning treatment
  • Same regimens given as chronic infection
Pregnancy and HCV

• Guidelines recommend treating HCV prior to pregnancy
• Mother to child transmission is low- 5-15% with progression to chronic infection 3-5%
• Children born to mothers with HCV need antibody-based screening at or after 18 months
• Avoid use during pregnancy, no human data available
What do you need to know?

• History
  – Risk factors for HCV acquisition (past and present)
  – Medical co-morbidities including coinfection with HBV or HIV
  – Alcohol and illicit drug use (past and present)
  – Psychiatric history
What do you need to know?

• History continued
  – Social (stable housing, transportation, support of family/friends)
  – Allergies
  – Medications, herbs, supplements, OTC (potential drug/drug interactions)
How healthy is the liver?

• Has the patient ever been treated for HCV?
  – Treatment naïve vs treatment experienced

• Any prior fibrosis testing?
  – History of a liver biopsy, Fibroscan or previous work-up? Important to document prior stage
How healthy is the liver?

• Is there evidence in their medical history of complications from liver disease?
  – Decompensated cirrhosis: presence of ascites, jaundice, coagulopathy, presence of esophageal varices, splenomegaly/portal hypertension, or hepatic encephalopathy
  – Prior hospitalizations for gastrointestinal bleed, ascites, history of paracentesis, AMS due to hepatic encephalopathy?
  – Refer these patients to Hepatology or GI
How healthy is the patient?

- Are there other significant comorbidities?
  - Uncontrolled DM, active TB, chronic kidney disease, coinfection with HIV or hepatitis B, undiagnosed cancer, substance use disorder

- Are there any extra-hepatic manifestations of liver disease?
  - fatigue (most common), depression, arthralgias, neuropathy, nephropathy, glomerulonephritis, lichen planus, non-Hodgkin’s lymphoma, porphyria cutanea tarda, and mixed cryoglobulinemia
Physical exam

• A complete PE at baseline is important
• Height, weight and BMI should be documented
• Look for liver related physical findings that would indicate advanced liver disease
  – Icterus, jaundice, spider nevi (angioma), ascites
  – Other possible signs: Terry’s nails, Caput medusa, gynecomastia, palmar erythema
Spider angioma
Icterus & Jaundice
Ascites and Caput Medusa
Testing for Asterixis
General laboratory evaluation

- CBC, CMP, PT/INR
- HCV RNA quantitative level (viral load)
- HCV genotype
- HIV screen
- HAV total IgG, hepatitis B surface antigen (HBsAg), surface antibody (Anti-HBs), core antibody (Anti-HBc)
  - Checking for HAV/HBV immunity and determining HBV status
- Pregnancy status
Immunizations

- All persons with HCV should be fully vaccinated for HAV and HBV
- Pneumococcal vaccination recommended for patients with cirrhosis or alcoholism
  - For more information, see handout
- Routine adult vaccines: influenza, TDaP, Shingrix after 50y
Hepatitis A

• Order Hepatitis A antibody total/IgG to check for immunity (not IgM)

• If non-reactive, give hepatitis A vaccine series
### Potential Reactivation of Hepatitis B

<table>
<thead>
<tr>
<th>RECOMMENDED</th>
<th>RATING</th>
</tr>
</thead>
<tbody>
<tr>
<td>All patients initiating HCV direct-acting antiviral therapy should be assessed for HBV coinfection with HBsAg testing and for evidence of prior infection with anti-HBs and anti-HBc testing.</td>
<td>Ila,B</td>
</tr>
</tbody>
</table>

Consult Liver Disease or Infectious Disease Specialist if HBsAg+ or anti-HBc+
Hepatitis B

• HBsAg+ Infection
• Anti-HBc+ Exposure. No need to vaccinate.
• Anti-HBs+ Immunity

Check patient’s vaccine history before initiating vaccine.
Evaluating fibrosis

• Why is it important?
  – Determines appropriate treatment & duration of treatment
  – To identify those with advanced disease who will need hepatocellular carcinoma (HCC) screening and additional long term follow up after cure
Metavir Scoring System for Liver Biopsy

STAGES (fibrosis)
- F0- no fibrosis
- F1- mild fibrosis (portal fibrosis without septa)
- F2- moderate fibrosis (portal fibrosis with few septa)
- F3- advanced fibrosis (numerous septa without cirrhosis)
- F4- cirrhosis

GRADES (inflammation)
- A0- no activity
- A1- mild activity
- A2- moderate activity
- A3- severe activity
How do you evaluate fibrosis?

Follow a stepwise approach:

• Start with non-invasive markers
  – Indirect and direct markers of fibrosis
• Radiologic imaging
• Liver biopsy
Hepatitis C Treatment

We want to keep you informed of recent drugs, screenings, treatments, and other news pertaining to Hepatitis and other liver diseases. As news becomes available we will post content here. Check back often to stay informed!

Treatment Tools
- Before Treatment
- Monitoring During and After Treatment
- Treatment Reference Tools

Staging Fibrosis
Start Here – Staging Fibrosis Algorithm
APRI and FIB-4 Interpretation

Treatment Naïve Decision Trees (click on Yes or No to begin)

<table>
<thead>
<tr>
<th>Genotype 1</th>
<th>Genotype 2 or 3</th>
<th>Genotype 4</th>
<th>Genotype 5 or 6</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cirrhosis?</td>
<td>Cirrhosis?</td>
<td>Cirrhosis?</td>
<td>Cirrhosis?</td>
</tr>
<tr>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>No</td>
<td>No</td>
<td>No</td>
<td>No</td>
</tr>
</tbody>
</table>

Treatment Experienced Patients
Consult Liver Disease Specialist
Indirect markers of fibrosis

- **APRI**
  - Uses AST and platelets
- **FIB-4**
  - Age, AST and ALT, platelet count
- Both are good at excluding or confirming minimal or significant fibrosis but less valuable for those somewhere in between

[www.hepatitis.uw.edu](http://www.hepatitis.uw.edu) or [www.mdcalc.com](http://www.mdcalc.com)
APRI

AST to Platelet Ratio Index:
   AST ÷ ULN of AST (40) ÷ Platelets (k/mL) x 100

• The lower the APRI score < 0.5 the greater the negative predictive value to rule out cirrhosis.
• The higher the APRI > 1.5 the greater the positive predictive value to rule in cirrhosis. APRI > 2.0 is 91% specific for cirrhosis.
• APRI alone is not sufficiently sensitive to rule out significant disease.
• The use of multiple indices in combination may result in higher diagnostic accuracy than APRI alone.
FIB-4

Fibrosis-4 score

- Age (years) x AST ÷ Platelets (k/mL) x √ALT
- Score < 1.45 has a negative predictive value of 90% for advanced fibrosis
- Score > 3.25 has a 97% specificity and 65% positive predictive value for advanced fibrosis

Fibrosis Case Study

- 56 y.o. female screened as Baby Boomer and found to be HCV Ab+, confirmed viral load 2,352,000 IU/mL
- Blood transfusion in 1983
- Does not use drugs or drink alcohol
- Baseline labs: Hgb 14, Hct 42.2, plt 354k, ALT 76, AST 60, alk phos 96, albumin 4.0, total bilirubin 0.3
  
  APRI = 0.4  FIB-4 = 1.09
## Interpretation of APRI and FIB-4

<table>
<thead>
<tr>
<th>APRI Result</th>
<th>Fibrosis Interpretation</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt; 0.5</td>
<td>No – Moderate Fibrosis</td>
</tr>
<tr>
<td>≥ 1.5</td>
<td>Advanced fibrosis (bridging fibrosis to cirrhosis)</td>
</tr>
<tr>
<td>&gt; 2</td>
<td>Cirrhosis</td>
</tr>
<tr>
<td>&gt; 0.5 &lt; 1.5</td>
<td>Indeterminate</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>FIB-4 Result</th>
<th>Fibrosis Interpretation</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt; 1.45</td>
<td>No-Moderate Fibrosis</td>
</tr>
<tr>
<td>&gt; 3.25</td>
<td>Advanced Fibrosis</td>
</tr>
<tr>
<td>1.45 – 3.25</td>
<td>Indeterminate</td>
</tr>
</tbody>
</table>
Serum Fibrosis Tests

- FibroTest/Quest
- Fibrosure LabCorps
- FibroSpect II/Prometheus
  - Use a proprietary algorithm that includes age, gender, and biochemical markers associated with hepatic fibrosis
    - Will give estimate of fibrosis stage
  - Contraindications to these tests: Gilbert disease, acute hemolysis, extrahepatic cholestasis, post-transplant, and renal insufficiency
  - 8-hour fast recommended
FibroSure Results

**FibroSure Components**
- Alanine aminotransferase (ALT)
- α2-macroglobulin
- Apolipoprotein A1
- Bilirubin, total
- γ-glutamyl transferase (GGT)
- Haptoglobin
- Patient's age and sex

*For more information, please contact your local account representative.*

<table>
<thead>
<tr>
<th>Test Name</th>
<th>Hepatitis C Virus (HCV) FibroSure*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Test Number</td>
<td>550123</td>
</tr>
</tbody>
</table>

**META VIR Group Scoring System**

<table>
<thead>
<tr>
<th>Fibrosis Stage (FibroTest)</th>
<th>Range</th>
</tr>
</thead>
<tbody>
<tr>
<td>F0 – No fibrosis</td>
<td>0.00-0.21</td>
</tr>
<tr>
<td>F0-F1</td>
<td>&gt;0.21-0.27</td>
</tr>
<tr>
<td>F1 – Portal fibrosis</td>
<td>&gt;0.27-0.31</td>
</tr>
<tr>
<td>F1-F2</td>
<td>&gt;0.31-0.48</td>
</tr>
<tr>
<td>F2 – Bridging fibrosis with few septa</td>
<td>&gt;0.48-0.58</td>
</tr>
<tr>
<td>F3 – Bridging fibrosis with many septa</td>
<td>&gt;0.58-0.72</td>
</tr>
<tr>
<td>F3-F4</td>
<td>&gt;0.72-0.74</td>
</tr>
<tr>
<td>F4 – Cirrhosis</td>
<td>&gt;0.74-1.00</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Activity Stage (ActiTest)</th>
<th>Range</th>
</tr>
</thead>
<tbody>
<tr>
<td>A0 – No activity</td>
<td>0.00-0.17</td>
</tr>
<tr>
<td>A0-A1</td>
<td>&gt;0.17-0.29</td>
</tr>
<tr>
<td>A1 – Minimal activity</td>
<td>&gt;0.29-0.36</td>
</tr>
<tr>
<td>A1-A2</td>
<td>&gt;0.36-0.52</td>
</tr>
<tr>
<td>A2 – Moderate activity</td>
<td>&gt;0.52-0.60</td>
</tr>
<tr>
<td>A2-A3</td>
<td>&gt;0.60-0.63</td>
</tr>
<tr>
<td>A3 – Severe activity</td>
<td>&gt;0.63-1.00</td>
</tr>
</tbody>
</table>

*For the most current information regarding test options, including specimen requirements and CPT codes, please consult the online Test Menu at www.LabCorp.com.*

**References**

FibroTest Result

Liver Fibrosis, FibroTest™ ActiTest™ Panel

- Fibro Test assesses the fibrosis of the liver
- Acti Test assesses activity (inflammation in chronic viral hepatitis C or B)

Biomarkers

<table>
<thead>
<tr>
<th>Analyte</th>
<th>Result</th>
<th>Reference Range/Comments</th>
<th>Analyte</th>
<th>Result</th>
<th>Reference Range/Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alpha2 Macroglobulin</td>
<td>301 H</td>
<td>106-279 mg/dL</td>
<td>Total Bilirubin</td>
<td>0.4</td>
<td>0.2-1.2 mg/dL</td>
</tr>
<tr>
<td>Haptoglobin</td>
<td>47</td>
<td>43-212 mg/dL</td>
<td>Gamma GT</td>
<td>63</td>
<td>3-70 U/L</td>
</tr>
<tr>
<td>Apolipoprotein A1</td>
<td>104</td>
<td>101-198 mg/dL</td>
<td>ALT</td>
<td>26</td>
<td>6-29 U/L</td>
</tr>
</tbody>
</table>
FIBROSpect II Results

1. FIBROSpect II Index
   Consistent with METAVIR F2-F4

2. Clinical Interpretation
   Based on this study population and these results, the chance of your patient having F2-F4 is 97.2%.
   The chance of having F0 is 0.0% and the chance of having F1 is 2.8%.

   *These values will vary with prevalence of F2-F4 fibrosis

3. METAVIR Description (1,2):
   - F0: No fibrosis
   - F1: Portal tract fibrosis
   - F2: Septal fibrosis
   - F3: Bridging fibrosis
   - F4: Cirrhosis

3. Reference Range Studies
   In a study population of chronic HCV patients (n=696) with a fibrosis (METAVIR F2-F4) prevalence of 51.7%, FIBROSpect II sensitivity at an index of 42 was 81% and the specificity was 71%. Tests performed to determine FIBROSpect II result: a-2-macroglobulin (A2M) by nephelometry, Tissue inhibitor of metalloproteinases-1 (TIMP-1) by ELISA, Hyaluronic acid (HA) by ELISA. This test was developed and its performance characteristics determined by Prometheus Laboratories Inc. It has not been cleared or approved by the U.S. Food and Drug Administration.
Staging Fibrosis in Untreated HCV

Do not use this to stage fibrosis in those who have been treated and achieved SVR

Calculate APRI, FIB-4*, and FibroScan if available.
If FibroScan not available obtain:
FibroSpect II (Prometheus), FibroSure (LabCorp)
FibroTest (Quest)
or available fibrosis test

Do Not Use APRI or FIB-4 if your patient is currently drinking EtOH (men > 3, women > 2 standard drinks daily), has acute HCV, or if your patient has known or suspected cirrhosis or advanced fibrosis, refer to liver specialist for fibrosis staging

Test results are concordant/unambiguous

No to moderate Fibrosis (Metavir F0-F2 equivalent)
Choose HCV treatment from Cirrhosis? “No” option

Advanced Fibrosis (Metavir F3 equivalent)
Choose HCV treatment from Cirrhosis? “No” option

Cirrhosis (Metavir F4 equivalent)
Choose HCV treatment from Cirrhosis? “Yes” option

RUQ US/AFP every 6 months for HCC screen. Consider referral to liver specialist.

Test results are discordant, indeterminant or unclear

Consult liver specialist about fibrosis staging

Click here for table Interpreting APRI and FIB-4

*https://www.hepatitisc.uw.edu/page/clinical-calculators/
Imaging to Estimate Fibrosis

- Abdominal U/S
- Transient U/S Elastography
- Magnetic Resonance Elastography
Abdominal U/S

• Advantages
  – Non-invasive, lower cost, widely available
  – Potential to identify useful factors
    • Nodularity, ascites, spleen size
    • Coarseness of the liver parenchyma
    • Size of lymph nodes around hepatic artery
    • Patency and flow of veins and arteries
    • Lesions suspicious for HCC

• RUQ vs abdominal U/S
Transient U/S Elastography

- Transient U/S Elastography Advantages
  - Measures liver stiffness with decent correlation with pathology
  - Painless, quick, easy to perform, reasonably accurate
  - Relatively inexpensive test

- FibroScan
  - Is a specific branded transient US elastography machine for measuring fibrosis, steatosis with limited availability in AK
  - Available at ANTHC and brought to tribal liver field clinics throughout the state
  - Has been studied for over 2 decades, starting in Europe
FibroScan
Exam XL (Liver)
Operator: tgh
Valid measurements: 10
Total measurements: 13
SWS MEDIAN = 1.20 m/s
SWS IQR = 0.05 m/s

<table>
<thead>
<tr>
<th>HCV</th>
<th>Indication: HCV</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Referring physician: TOWNSEND</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>CAP (dB/m)</th>
<th>E (kPa)</th>
</tr>
</thead>
<tbody>
<tr>
<td>IQR</td>
<td>MEDIAN</td>
</tr>
<tr>
<td>44</td>
<td>300</td>
</tr>
<tr>
<td>MEDIAN</td>
<td>4.3</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>#1</th>
<th>#2</th>
<th>#3</th>
<th>#4</th>
<th>#5</th>
<th>#6</th>
<th>#7</th>
<th>#8</th>
</tr>
</thead>
<tbody>
<tr>
<td>259 dB/m</td>
<td>278 dB/m</td>
<td>329 dB/m</td>
<td>306 dB/m</td>
<td>298 dB/m</td>
<td>293 dB/m</td>
<td>330 dB/m</td>
<td>315 dB/m</td>
</tr>
<tr>
<td>4.9 kPa</td>
<td>4.7 kPa</td>
<td>4.0 kPa</td>
<td>4.1 kPa</td>
<td>4.2 kPa</td>
<td>4.0 kPa</td>
<td>4.1 kPa</td>
<td>5.2 kPa</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>#9</th>
<th>#10</th>
</tr>
</thead>
<tbody>
<tr>
<td>279 dB/m</td>
<td>356 dB/m</td>
</tr>
<tr>
<td>4.5 kPa</td>
<td>4.4 kPa</td>
</tr>
</tbody>
</table>

Alaska Native Medical Center
3900 Ambassador Drive
99508 Anchorage AK
USA
907-729-1500

10/24/2018
12:22:23 PM
Interpretation of FibroScan with CAP

### CAP Performance By Steatosis Grade

<table>
<thead>
<tr>
<th>Grade</th>
<th>CAP Cutoff dB/M</th>
<th>Sensitivity</th>
<th>Specificity</th>
<th>AUC</th>
</tr>
</thead>
<tbody>
<tr>
<td>S0 vs S1-S3</td>
<td>248</td>
<td>0.69</td>
<td>0.82</td>
<td>0.82</td>
</tr>
<tr>
<td>S0-S1 vs S2-S3</td>
<td>268</td>
<td>0.77</td>
<td>0.81</td>
<td>0.86</td>
</tr>
<tr>
<td>S0-S2 vs S3</td>
<td>280</td>
<td>0.88</td>
<td>0.78</td>
<td>0.88</td>
</tr>
</tbody>
</table>

### Steatosis Grade

<table>
<thead>
<tr>
<th>Steatosis Grade</th>
<th>Affected Hepatocytes</th>
</tr>
</thead>
<tbody>
<tr>
<td>S0</td>
<td>&gt; 33 %</td>
</tr>
<tr>
<td>S1</td>
<td>≤ 33 %</td>
</tr>
<tr>
<td>S2</td>
<td>&gt; 33 – 66 %</td>
</tr>
<tr>
<td>S3</td>
<td>&gt; 66 %</td>
</tr>
</tbody>
</table>

### FibroScan Peer Review Cutoff Value Reference

<table>
<thead>
<tr>
<th>Disease</th>
<th>F0-F1</th>
<th>F2</th>
<th>F3</th>
<th>F4</th>
</tr>
</thead>
<tbody>
<tr>
<td>HBV</td>
<td>≤ 6.0</td>
<td>&gt; 6.0</td>
<td>≥ 9.0</td>
<td>≥ 12.0</td>
</tr>
<tr>
<td>HCV</td>
<td>≤ 7.0</td>
<td>&gt; 7.0</td>
<td>≥ 9.5</td>
<td>≥ 12.0</td>
</tr>
<tr>
<td>HCV-HIV</td>
<td>≤ 7.0</td>
<td>≤ 10.0</td>
<td>≥ 11.0</td>
<td>≥ 14.0</td>
</tr>
<tr>
<td>Cholestatic</td>
<td>≤ 7.0</td>
<td>≥ 7.5</td>
<td>≥ 10.0</td>
<td>≥ 17.0</td>
</tr>
<tr>
<td>NAFLD/NASH</td>
<td>≤ 7.0</td>
<td>≥ 7.5</td>
<td>≥ 10.0</td>
<td>≥ 14.0</td>
</tr>
</tbody>
</table>

Utilization of FibroScan in Clinical Practice; Bonder et al, Current Gastroenterology Rep, 2014 16-372

Study Meta-Analysis / 2076 Subjects
Transient U/S Elastography

Disadvantages

– Operator dependent
– Can be difficult on patient’s with significant central adiposity
– Not meant to diagnose liver mass
Magnetic Resonance Elastography

• When would you need this?
• Advantages
  – Good correlation with pathology results
  – More accurate b/c not operator dependent
  – Can be used in conjunction with contrast enhanced MRI
  – Will give more information about the liver, cirrhosis, and hepatomas
Magnetic Resonance Elastography

• Disadvantages
  – Limited availability
  – Cost
Liver Biopsy

• **Advantages**
  – Gold standard
  – Measures grade (inflammation) and stage (fibrosis)
  – Diagnose co-existing liver diseases

• **Disadvantages**
  – Invasive, has associated risks, higher cost than U/S
  – Sampling variability
  – Can incorrectly stage fibrosis 20% of time
Indications for MRE or Liver Biopsy

• If indirect, serum markers and TE/FibroScan show discordant results and the decision on how to manage patient with HCV depends on results (MRE)
  – To determine if patient requires lifelong surveillance for HCC

• When concurrent forms of liver disease in addition to HCV suspected (consider liver biopsy)
Case Study 1

• A 59 yo (born 1959) male presented recently as a new patient
• Labs revealed elevated LFTs so follow up testing done, found to be HCV Ab+
• PMH: HTN, prediabetes, obesity, GERD
• Medications: lisinopril 20 mg daily and omeprazole 20 mg daily. No OTCs or herbals.
• Social hx: Doesn’t use drugs or tobacco. He enjoys beer (in moderation) on the weekends.
• Family hx – Negative for liver disease. Father died of colon ca at age 64, mother, 80, alive & well
Case Study 1

• Is there additional health or social history you do you need?
  • Are other health screenings up-to-date?
  • Housing/work/transportation issues
PTDs?

Potential Treatment Disruptors
Case Study 1 Physical Exam

- BMI 34.7
- No icterus or jaundice
- Several spider nevi on upper chest
- Abd distended, truncal obesity
- No asterixis
Case Study 1 Baseline Labs

- CBC: Hgb 14.1, Hct 41.5, plt 139
- CMP: Glucose 97, creatinine 0.8, eGFR 97, electrolytes normal, ALT 91, AST 112, alkaline phosphatase 114, total bilirubin 1.2, albumin 3.4
- PT/INR = 13.9, 1.1
- HCV RNA 1,974,000 international units/mL
- Genotype 1a
- HIV negative
- HBsAg negative, HBcAb negative, HBsAb negative
- HAV IgG reactive

APRI is 2.01 and FIB-4 is 4.98
Interpretation of APRI/FIB-4 Link

### Interpretation of APRI and FIB-4

<table>
<thead>
<tr>
<th>APRI Result</th>
<th>Fibrosis Interpretation</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt; 0.5</td>
<td>No – Moderate Fibrosis</td>
</tr>
<tr>
<td>≥ 1.5</td>
<td>Advanced fibrosis (bridging fibrosis to cirrhosis)</td>
</tr>
<tr>
<td>&gt; 2</td>
<td>Cirrhosis</td>
</tr>
<tr>
<td>&gt; 0.5 &lt; 1.5</td>
<td>Indeterminate</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>FIB-4 Result</th>
<th>Fibrosis Interpretation</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt; 1.45</td>
<td>No-Moderate Fibrosis</td>
</tr>
<tr>
<td>&gt; 3.25</td>
<td>Advanced Fibrosis</td>
</tr>
<tr>
<td>1.45 – 3.25</td>
<td>Indeterminate</td>
</tr>
</tbody>
</table>
It looks like my patient has cirrhosis, now what?
Further Evaluation Needed

• Confirm finding with another test – serum fibrosis test or TE/FibroScan
• Baseline abd ultrasound then RUQ ultrasound to screen for hepatocellular carcinoma (HCC) every 6 months
• Calculate Child-Turcotte-Pugh (CTP) Score when someone has cirrhosis
Case Study 1 Ultrasound

- Liver has increased hepatic echogenicity consistent with medical liver disease. No hepatic mass. Mild splenomegaly. Hepatopetal blood flow in the portal vein. Small amount of ascites present.
Hepatitis C Treatment

We want to keep you informed of recent drugs, screenings, treatments, and other news pertaining to Hepatitis and other liver diseases. As news becomes available we will post content here. Check back often to stay informed!

Treatment Tools

- Before Treatment
  - Treatment Checklist
  - Health Summary
  - Insurance Screening
  - Patient Readiness Attestation
  - Hep C Information
  - Pre-Treatment Letter
  - Alcohol Use Disorders Identification Test (Audit-C)
  - Patient Health Questionnaire (PHQ-9)
  - Child-Turcotte-Pugh (CTP) Calculator
  - Hep Drug Interactions

- Monitoring During and After Treatment

- Treatment Reference Tools
**CTP Score to Determine if Patient Has Compensated or Decompensated Cirrhosis**

<table>
<thead>
<tr>
<th>LAB OR CLINICAL CRITERIA</th>
<th>POINTS*</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>1</td>
</tr>
<tr>
<td>Encephalopathy</td>
<td>None</td>
</tr>
<tr>
<td>Ascites</td>
<td>None</td>
</tr>
<tr>
<td>Bilirubin (mg/dL)</td>
<td>&lt;2</td>
</tr>
<tr>
<td>Albumin (g/dL)</td>
<td>&gt;3.5</td>
</tr>
<tr>
<td>INR</td>
<td>&lt;1.7</td>
</tr>
</tbody>
</table>

Add score for each criteria.

**CTP Class:**
- A = 5-6 points (compensated)
- B = 7-9 points (decompensated)
- C = 10-15 points (decompensated)

Case Study 1 Baseline Labs

- CBC: Hgb 14.1, Hct 41.5, plt 139
- CMP: Glucose 97, creatinine 0.8, eGFR 97, electrolytes normal, ALT 91, AST 112, alkaline phosphatase 114, total bilirubin 1.2, albumin 3.4
- PT/INR = 13.9, 1.1
- HCV RNA 1,974,000 international units/mL
- Genotype 1a
- HIV negative
- HBsAg negative, HBcAb negative, HBsAb negative
- HAV IgG reactive

APRI is 2.01 and FIB-4 is 4.98
This patient seems a little complicated...

Consult/AK Echo
- Discordant fibrosis results
- Acute hepatitis C
- Compensated cirrhosis
- Other contributing factors to liver disease
- Failed prior HCV therapy
- Anyone who seems like a challenge but you think you can handle with a little guidance

Refer to GI, hepatology or ID
- Co-infected with HIV or HBV
- HCC
- Decompensated cirrhosis
- Dialysis
- Prior or future transplant
What else should you be aware of?

• HCV can co-exist with other forms of liver disease
  – Alcoholic hepatitis (history, AST/ALT ratio, GGT)
  – NAFLD and NASH
  – Alpha-1 Antitrypsin Deficiency
  – Hemochromatosis
  – Autoimmune hepatitis

Workup of elevated LFTs: [https://anthc.org/what-we-do/clinical-and-research-services/hep/for-providers/](https://anthc.org/what-we-do/clinical-and-research-services/hep/for-providers/)
In Summary

• HCV treatment evaluation needs to be wholistic
• Identifying fibrosis level is a key part of that evaluation
• Common barriers to consider are behavioral health issues, housing, transportation, and substance use disorders
• Are you ready? It takes a team to treat HCV
Thank you for your attention

My Contact Info:
ltownshend@anthc.org
Phone: 729-1573

Website: anthc.org/hep